Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome in Breast Cancer Patients
NCT05165069Phase 3Active, not recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2022
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of mecobalamin in hand-foot syndrome (HFS), sponsored by Sun Yat-sen Memorial Hospital. Started Jan 2022; status: active, not recruiting.
02
Drugs
mecobalamin
03
Conditions
hand-foot syndrome (HFS)
Beyond the preview
Go deeper on NCT05165069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05165069.